Rx Imports Will Resolve Shortage Of Injectable Nutrition Drugs After Congressional Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Fresenius Kabi USA’s Norway plant is to supply the US with three injectable drugs used in total parenteral nutrition, primarily for treatment of premature infants; FDA has previously permitted importation of 11 other drugs that have been subject to shortages.
You may also be interested in...
Doxil Shortage Solution: FDA Chooses Middle Ground, Allows Import Of Unapproved Version
FDA is allowing Sun Pharma Global FZE to import its unapproved liposomal version of doxorubicin, Lipodox, to alleviate a shortage, but has not yet given the drug full approval.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.